Carmustine decreases amyloid beta plaques

Long term treatment by carmustine, a chemical relative of mustard gas and already used to treat some types of brain cancer, can decrease the amount of amyloid β and number of amyloid plaques in a mouse model of Alzheimer's disease. The research is published in Biomed Central's open access journal BMC Medicine.

Alzheimer's disease progressively destroys memory, language, and judgement of affected people. While deaths due to heart disease, stroke and cancer may be decreasing, the number of deaths each year due to Alzheimer's disease is on the increase. Accumulation of amyloid β plaques can be seen in the brain from early stages, even though the exact relationship between these plaques and Alzheimer's disease has not yet been firmly established.

Noticing that people with cancer tended not to get Alzheimer's disease, and vice versa, researchers from the Florida based Torrey Pines Institute for Molecular Studies screened a library of all FDA approved anti- for their ability to reduce amyloid β levels in cells expressing amyloid . From this screen they found that carmustine could decrease conversion of precursor protein to amyloid β levels by 60%.When tested in a mouse model of Alzhiemer's disease, long term treatment with carmustine was able to reduce amyloid β levels by 75%.

Discussing how this research could translate to humans Dr Madepalli Lakshmana, who led this study commented, "The level of carmustine needed to achieve reduction in amyloid β is much lower than the dose already used in the treatment of some types of brain cancer. Also carmustine does not appear to act by activating or by blocking secretases which reduces possible side effects seen with other anti-amyloid investigational . While more work still needs to be done carmustine appears to be a powerful candidate drug for treatment and prevention of Alzheimer's disease."

More information: Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine Crystal D Hayes, Debleena Dey, Juan Pablo Palavicini, Hongjie Wang, Kshitij A Patkar, Dmitriy Minond, Adel Nefzi and Madepalli K Lakshmana BMC Medicine 2013, 11:81 doi:10.1186/1741-7015-11-81

Commentary: Potential repurposing of oncology drugs for the treatment of Alzheimer's disease, Wataru Araki BMC Medicine 2013, 11:82 doi:10.1186/1741-7015-11-82

add to favorites email to friend print save as pdf

Related Stories

Asthma drug could help control or treat Alzheimer's disease

Mar 25, 2011

A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's ...

Road block as a new strategy for the treatment of Alzheimer's

Aug 22, 2011

Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Anti-inflammatory drug blocks brain plaques

Jun 24, 2008

Brain destruction in Alzheimer's disease is caused by the build-up of a protein called amyloid beta in the brain, which triggers damaging inflammation and the destruction of nerve cells. Scientists had previously shown that ...

Recommended for you

Improving the quality of dementia care

Nov 20, 2014

Healthcare workers and facilitators caring for persons suffering with dementia have expressed their satisfaction with new forms of mobile phone apps which are designed to assist support carers in residential homes to be more ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.